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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Aminoglycosides possess in vitro activity against aerobic and
facultative Gram-negative bacilli. However, nationwide surveillance on susceptibility data of
Acinetobacter baumannii complex and Pseudomonas aeruginosa to aminoglycosides was
limited, and aminoglycoside resistance has emerged in the past decade. We study the
in vitro susceptibility of A. baumannii complex and other nonfermentative Gram-negative
bacilli (NFGNB) to aminoglycosides.
Methods: A total of 378 NFGNB blood isolates causing healthcare-associated bloodstream in-
fections during 2008 and 2013 at four medical centers in Taiwan were tested for their suscep-
tibilities to four aminoglycosides using the agar dilution method (gentamicin, amikacin,
tobramycin, and isepamicin) and disc diffusion method (isepamicin).t of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei City,
.tw (W.-H. Sheng).
.07.010
Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
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Gram-negative
bacilliResults: A. baumannii was highly resistant to all four aminoglycosides (range of susceptibility,
0e4%), whereas >80% of Acinetobacter nosocomialis and Acinetobacter pittii blood isolates
were susceptible to amikacin (susceptibility: 96% and 91%, respectively), tobramycin (suscep-
tibility: 92% and 80%, respectively), and isepamicin (susceptibility: 96% and 80%, respec-
tively). All aminoglycosides except gentamicin possessed good in vitro activity (>94%)
against P. aeruginosa. Amikacin has the best in vitro activity against P. aeruginosa (suscepti-
bility, 98%), followed by A. nosocomialis (96%), and A. pittii (91%), whereas tobramycin and
isepamicin were less potent against A. pittii (both 80%). Aminoglycoside resistances were
prevalent in Stenotrophomonas maltophilia and Burkholderia cepacia complex blood isolates
in Taiwan.
Conclusion: Genospecies among the A. baumannii complex had heterogeneous susceptibility
profiles to aminoglycosides. Aminoglycosides, except gentamicin, remained good in vitro
antimicrobial activity against P. aeruginosa. Further in vivo clinical data and continuous resis-
tance monitoring are warranted for clinical practice guidance.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Nonfermentative Gram-negative bacilli (NFGNB) are the
leading pathogens that cause nosocomial bacteremia and
infections.1 They result in high fatality in critically ill pa-
tients and in patients with septic shock and bacteremia. The
mortality rate attributed to NFGNB bacteremia could be as
high as 25%.2,3 Among NFGNB, Pseudomonas aeruginosa,
Acinetobacter baumannii complex, and Stenotrophomonas
maltophilia were the most common pathogens causing
healthcare-associated bloodstream infections.3
NFGNB are easily resistant to most of the beta-lactam
antibiotics through beta-lactamase production, imperme-
ability, and multidrug efflux pumps.4 The emerging resis-
tance of NFGNB to all commonly used antibiotics may lead
to inappropriate administration of empirical antibiotics,
which contributes to the high fatality rate of NFGNB
bacteremia.2,5,6 The limitation of the susceptible antibiotic
spectrum also makes the clinical treatment more difficult.
Therefore, periodic active surveillance for the epidemi-
ology of NFGNB resistance is crucial for infection control
and antibiotic stewardship.
Aminoglycosides possess in vitro activity against many
aerobic and facultative Gram-negative bacilli, like P. aer-
uginosa and Acinetobacter spp., and they are intrinsically
inactive against some NFGNB, such as S. maltophilia and
Burkholderia cepacia complex. Therefore, the amino-
glycosides are the drug of choice for antimicrobial combi-
nation for severe infections (e.g., bacteremia) caused by
NFGNB.7 However, resistance to aminoglycosides in P. aer-
uginosa and Acinetobacter spp. can develop by enzymatic
modification, impermeability, or MexXY (also referred to as
AmrAB) efflux pumps.6,8 The susceptibility data of NFGNB
to aminoglycosides were limited in Taiwan, and the previ-
ous study did not differentiate A. baumannii complex into
the species level for investigation.9 In this study, we aimed
to compare the in vitro susceptibility of NFGNB blood iso-
lates to aminoglycosides in patients with healthcare-
associated bacteremia in Taiwan.Methods
Bacterial isolates
Healthcare-associated bloodstream infections were defined
as bacteremia occurring in patients admitted over 48 hours,
in patients with recent hospitalization history within 90
days, in patients who were nursing home residents, and in
patients who were frequent visitors of the hemodialysis
facility or the hospital-based clinic. Blood isolates of NFGNB
collected during 2008 to 2013 and preserved at four medical
centers in Taiwan were retrospectively recruited using their
collection numbers from the laboratory. The four hospitals
included National Taiwan University Hospital (NTUH) and
Taipei Veterans General Hospital (TVGH) located in north-
ern Taiwan; China Medical University Hospital (CMUH)
located in central Taiwan; and Kaohsiung Chang Gung Me-
morial Hospital (KCGMH) located in southern Taiwan. A
total of 378 available NFGNB isolates (NTUH, 319 isolates;
TVGH, 18 isolates; CMUH, 32 isolates; and KCGMH, 9 iso-
lates) retrospectively identified from 2013 isolates were
randomly selected by the collection numbers for amino-
glycoside susceptibility testing. Those isolates included P.
aeruginosa (100 isolates), A. baumannii (76 isolates), Aci-
netobacter nosocomialis (54 isolates), Acinetobacter pittii
(45 isolates), S. maltophilia (50 isolates), and B. cepacia
complex (53 isolates). None of the patients had duplicate
bacterial isolates in this study.Bacterial identification
The species of all isolates, including A. baumannii complex
strains, were routinely identified using standard conven-
tional microbiological methods or by the Vitek System
(bioMe´rieux, Hazelwood, MO, USA) as required. The geno-
species of A. baumannii strains were further identified
according to the sequence of the 16S-23S rRNA gene
intergenic spacer region as previously described.10
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Gentamicin supplied by Schering Plough (Bloomfield, NJ,
USA), amikacin by Bristol-Myers Squibb (Princeton, NJ,
USA), tobramycin by Eli Lilly (Indianapolis, IN, USA), and
isepamicin by TTY Biopharm (Taipei, Taiwan) were used for
susceptibility testing using the agar dilution method.
The minimal inhibitory concentration (MIC) for each
aminoglycoside to the isolated bacteria was determined
using the agar dilution method according to the Clinical and
Laboratory Standards Institute (CLSI) standard procedure
protocol. The susceptibility to gentamicin, amikacin, and
tobramycin was also determined according to the MIC
interpretive criteria suggested by CLSI.11 Given that there is
no consensus susceptibility criteria for isepamicin, the
same MIC interpretive criteria for amikacin was applied to
isepamicin as follows: susceptible, 16 mg/mL; intermedi-
ate, 32 mg/mL; resistant, 64 mg/mL. Because there is no
consensus clinical breakpoint for S. maltophilia and B.
cepacia complex either, the same susceptibility criteria for
P. aeruginosa was applied for these two clinical species as
follows: (for gentamicin, tobramycin) susceptible, 4 mg/
mL; intermediate, 8 mg/mL; resistant, 16 mg/mL; (for
amikacin) susceptible, 16 mg/mL; intermediate, 32 mg/
mL; resistant, 64 mg/mL. The disk diffusion test to ise-
pamicin for the isolated bacteria was also performed ac-
cording to CLSI standard protocol12 The zone diameter
interpretive criteria for amikacin were applied for the
isepamicin because of the same reason: susceptible,
17 mm; intermediate, 15e16 mm; resistant, 14 mm.
Escherichia coli American Type Culture Collection (ATCC;
Rockville, MD, USA) 25922 and P. aeruginosa ATCC 27853
were used for daily quality control testing as recommended
by the CLSI.
Statistical analysis
Susceptibility data were classified as dichotomous out-
comes, which were compared using chi-square statistics,
and p < 0.05 was defined as statistically significant. For
comparisons between multiple groups, the logistic regres-
sion model was used. Data were analyzed using Stata
software, version 12 (StataCorp, College Station, TX, USA).Results
In vitro susceptibility of NFGNB to aminoglycosides
using the agar dilution method
In vitro susceptibilities of the 378 blood isolates of NFGNB
to aminoglycosides were determined according to MIC using
the agar dilution method (Table 1). Three species in A.
baumannii complex have different susceptibility profiles to
aminoglycosides. A. baumannii was highly resistant to all
four aminoglycosides. However, >80% of A. nosocomialis
isolates and A. pittii isolates were susceptible to amikacin,
tobramycin, and isepamicin, but not to gentamicin. Among
the tested aminoglycosides, amikacin possessed the best
in vitro activity against both A. nosocomialis (susceptibil-
ity: 96%, MIC90: 8 mg/mL) and A. pittii (susceptibility: 91%,MIC90: 16 mg/mL). Tobramycin had similar high activity to
isepamicin against A. nosocomialis (susceptibility: 92% vs.
96%, respectively; and MIC90: 4 mg/mL and 8 mg/mL,
respectively), however, their activities against A. pittii
were moderate (susceptibility: 80% for both; and MIC90:
8 mg/mL and 32 mg/mL, respectively). Gentamicin had poor
activity against the current A. baumannii complex. The
differences in susceptibility rates to the four aminoglyco-
sides between A. baumannii and A. nosocomialis, A. bau-
mannii and A. pittii, and among the three A. baumannii
complex strains were all statistically significant (p < 0.001).
All four aminoglycosides still had good activity against
current P. aeruginosa blood isolates from patients with
healthcare-associated bloodstream infections in Taiwan.
The susceptibility rates of the P. aeruginosa isolates to
isepamicin, amikacin, tobramycin, and gentamicin were
99%, 98%, 98%, and 94%, respectively. The MIC90 values of
isepamicin, amikacin, tobramycin, and gentamicin for the
P. aeruginosa isolates were 8 mg/mL, 4 mg/mL, 1 mg/mL,
and 4 mg/mL, respectively.
Both the S. maltophilia and B. cepacia complex isolates
were intrinsically resistant to all four aminoglycosides. The
susceptible rates of S. maltophilia isolates to aminoglyco-
sides varied from 4% to 10% with all the MIC90 values being
>128 mg/mL. The susceptible rates of B. cepacia complex
isolates varied from 4% to 8% with all the MIC90 values being
>128 mg/mL.
Comparing the activities of the four aminoglycosides
against the 378 NFGNB isolates from patients with
healthcare-associated bloodstream infections in Taiwan,
amikacin possessed the greatest activity against P. aerugi-
nosa (susceptibility: 98%), A. nosocomialis (susceptibility:
96%), and A. pittii (susceptibility: 91%), but poor activity
against A. baumannii (susceptible: 4%), S. maltophilia
(susceptible: 4%), and B. cepacia complex (susceptible:
6%); tobramycin and isepamicin had lesser activity against
A. pittii (susceptibility: 80% for both aminoglycosides)
compared to amikacin. Among all NFGNB isolates in this
study, only P. aeruginosa was still highly susceptible to all
four aminoglycosides.In vitro susceptibility of NFGNB to isepamicin by
the disc diffusion method
Zone diameter results and the susceptibility rates of NFGNB
isolates to isepamicin using the disc diffusion method are
listed in Table 2. Isepamicin possessed good activity against
A. nosocomialis (susceptibility: 94%) and P. aeruginosa
(susceptibility: 99%), but had poor activity against A. bau-
mannii (susceptible: 4%), S. maltophilia (susceptible: 26%),
and B. cepacia complex (susceptible: 17%); these results
were similar to those by the agar dilution method. How-
ever, the susceptibility rate of A. pittii to isepamicin was
better using the disc diffusion method than by using the
agar dilution method (the susceptibility was 91% in the disk
diffusion method and 80% in the agar dilution method). The
differences in the susceptibility rates to isepamicin using
the disc diffusion method between A. baumannii and A.
nosocomialis, A. baumannii and A. pittii, and among the
three A. baumannii complex strains were all statistically
significant (p < 0.001). Except for S. maltophilia
Table 2 In vitro susceptibility of blood isolates of nonfermentative Gram-negative bacilli (NFGNB) to isepamicin using the disc
diffusion method and the agar dilution method.
Bacterium
(no. of isolates tested)
Zone diameter (nearest whole mm) Susceptibility (no. of
isolates tested) by disc
diffusion method
Susceptibility (no. of
isolates tested) by agar
dilution method
pa
Range S I R S I R
Acinetobacter
baumannii (75)
6e21 4 (3) 0 (0) 96 (72) 4 (3) 0 (0) 96 (73) 1.000
Acinetobacter
nosocomialis (54)
3e24 94 (51) 0 (0) 6 (3) 96 (52) 0 (0) 4 (2) 0.647
Acinetobacter
pittii (45)
6e26 91 (41) 0 (0) 9 (4) 80 (36) 13 (6) 7 (3) 0.134
Stenotrophomonas
maltophilia (50)
6e25 26 (13) 18 (9) 56 (28) 10 (5) 2 (1) 88 (44) 0.037
Burkholderia
cepacia complex (53)
6e33 17 (9) 4 (2) 79 (42) 8 (4) 8 (4) 84 (45) 0.139
Pseudomonas
aeruginosa (100)
13e31 99 (99) 0 (0) 1 (1) 99 (99) 0 (0) 1 (1) 1.000
a Comparison of in vitro susceptibility by the disc diffusion method and the agar dilution method.
I Z intermediate; R Z resistant; S Z susceptible.
Table 1 In vitro susceptibility of blood isolates of nonfermentative Gram-negative bacilli (NFGNB) to aminoglycosides using
the agar dilution method.
Bacterium
(no. of isolates tested)
Antimicrobial
agents
MIC (mg/L) Susceptibility (no. of isolates
tested)
p
Range MIC50 MIC90 S I R
Acinetobacter
baumannii (76)
Gentamicin 64e>128 >128 >128 0 (0) 0 (0) 100 (76) < 0.001a
Amikacin 4e>128 >128 >128 4 (3) 0 (0) 96 (73) < 0.001a
Tobramycin 2e>128 >128 >128 5 (4) 1 (1) 94 (71) < 0.001a
Isepamicin 2e>128 >128 >128 4 (3) 0 (0) 96 (73) < 0.001a
Acinetobacter
nosocomialis (54)
Gentamicin 1e>128 8 16 30 (16) 48 (26) 22 (12) < 0.001b
Amikacin 4e>128 8 8 96 (52) 0 (0) 4 (2) < 0.001b
Tobramycin 1e>128 2 4 92 (50) 4 (2) 4 (2) < 0.001b
Isepamicin 2e>128 4 8 96 (52) 0 (0) 4 (2) < 0.001b
Acinetobacter
pittii (45)
Gentamicin 1e>128 8 32 44 (20) 38 (17) 18 (8) < 0.001c
Amikacin 2e>128 4 16 91 (41) 4 (2) 4 (2) < 0.001c
Tobramycin 0.5e>128 2 8 80 (36) 16 (7) 4 (2) < 0.001c
Isepamicin 2e>128 8 32 80 (36) 13 (6) 7 (3) < 0.001c
Stenotrophomonas
maltophilia (50)
Gentamicin 2e>128 128 >128 4 (2) 6 (3) 90 (45)
Amikacin 4e>128 128 >128 4 (2) 4 (2) 92 (46)
Tobramycin 2e>128 128 >128 4 (2) 2 (1) 94 (47)
Isepamicin 4e>128 128 >128 10 (5) 2 (1) 88 (44)
Burkholderia cepacia
complex (53)
Gentamicin 0.5e>128 >128 >128 4 (2) 0 (0) 96 (51)
Amikacin 2e>128 >128 >128 6 (3) 11 (6) 83 (44)
Tobramycin 2e>128 128 >128 4 (2) 0 (0) 96 (51)
Isepamicin 1e>128 128 >128 8 (4) 8 (4) 84 (45)
Pseudomonas
aeruginosa (100)
Gentamicin 1e>128 2 4 94 (94) 2 (2) 3 (3)
Amikacin 5e32 4 4 98 (98) 2 (2) 0 (0)
Tobramycin 0.25e>128 1 1 98 (98) 0 (0) 2 (2)
Isepamicin 1e64 4 8 99 (99) 0 (0) 1 (1)
a Comparison of in vitro susceptibility of all three Acinetobacter baumannii complex species.
b Comparison of in vitro susceptibility of Acinetobacter baumannii and Acinetobacter nosocomialis.
c Comparison of in vitro susceptibility of Acinetobacter baumannii and Acinetobacter pittii.
IZ intermediate; MICZminimal inhibitory concentration; MIC50Zminimum concentration inhibiting 50% of isolates; MIC90Zminimum
concentration inhibiting 90% of isolates; R Z resistant; S Z susceptible.
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922 J.-Y. Liu et al.(p Z 0.037), there were no discrepancies of antimicrobial
susceptibilities of aminoglycosides against other NFGNB
blood isolates between the agar dilution method and the
disc diffusion method (all p > 0.05). There was high cate-
gorical agreement between the susceptibility rates deter-
mined using the disc diffusion method and the agar dilution
method (Pearson correlation coefficient r Z 0.9887,
p Z 0.0002).Discussion
Our study demonstrated different in vitro susceptibilities to
aminoglycosides among genospecies of A. baumannii com-
plex. In addition, P. aeruginosa isolates from nosocomial
bacteremia in Taiwan remained highly susceptible to amino-
glycosides. Finally, amikacin possessed the widest spectrum
coverage among the four aminoglycosides against NFGNB,
including P. aeruginosa, A. nosocomialis, and A. pittii.
A. baumannii complex comprises Acinetobacter geno-
species 1 (A. calcoaceticus), genospecies 2 (A. baumannii),
genospecies 3 (A. pittii), and genospecies 13TU (A. noso-
comialis). They are phenotypically similar and the com-
mercial identification system has limited capacity to
differentiate between them.13,14 Compared to A. nosoco-
mialis and A. pittii, A. baumannii had higher carbapenem
resistance and corresponded to higher attributable mor-
tality of the patients with A. baumannii bacteremia.14
Previous studies showed different resistant mechanisms of
A. baumannii from A. nosocomialis and A. pittii, and the
results of the susceptibility to aminoglycosides varied.15e17
Most of the studies showed high resistant rates of A. bau-
mannii to gentamicin, amikacin, tobramycin, and
isepamicin.14,15,17e19 However, susceptibilities of A. noso-
comialis and A. pittii to aminoglycosides were not consis-
tent between studies, with the susceptibility rates varied
from 22% to 80.6% for A. nosocomialis and 25% to 66.7% for
A. pittii.14,15 The sample sizes of the blood isolates of A.
nosocomialis and A. pittii in those studies were limited,
especially in data from Taiwan.9,14e18 None of the previous
studies provided the susceptibility of A. nosocomialis and
A. pittii to isepamicin. Our study revealed that both ise-
pamicin and amikacin produced similar activities against A.
baumannii complex. Consistent with these studies,9,14e18
our results showed high resistance of A. baumannii to all
four aminoglycosides in patients with nosocomial A. bau-
mannii bacteremia in Taiwan. Nevertheless, aminoglyco-
sides, except gentamicin, still possessed good activity
against A. nosocomialis and A. pittii in nosocomial
bacteremic patients (>80% isolates were susceptible),
especially for amikacin (96% of the A. nosocomialis isolates
and 91% of the A. pittii isolates were susceptible to ami-
kacin). These results implied the importance of genospe-
cies differentiation of the A. baumannii complex for
clinical treatment guidance.
P. aeruginosa was the leading NFGNB that caused noso-
comial NFGNB bacteremia.3,20 Increasing prevalence of
multidrug resistant P. aeruginosa even worsened the clin-
ical treatment, with increased mortality rate in bacteremic
patients.4,8,21e24 Chromosomally encoding both RmtD
methylase and metallo-b-lactamases genes have also been
found leading to pan-drug resistant P. aeruginosa.25,26 Fewantibiotics were available and were susceptible to P. aer-
uginosa when it was resistant to beta-lactam antibiotics
due to cross-resistance. Compared to carbapenems and
quinolones, aminoglycosides have the lowest cross-
resistance and coresistance rates for piperacillin-resistant
P. aeruginosa.5,21 Our current study showed high suscepti-
bility of P. aeruginosa to all aminoglycosides in nosocomial
bacteremic patients in Taiwan. However, several studies
have shown increasing resistance of gentamicin and
tobramycin with resistant rates around 15e30% in P. aeru-
ginosa isolates in Taiwan.9,25 Overall, amikacin and prob-
ably isepamicin, remained active for P. aeruginosa,
however, emerging multidrug resistance to aminoglycosides
should be monitored regularly and intensively.
All four aminoglycosides had poor activity against S.
maltophilia and B. cepacia complex isolates in our study,
which was consistent with the previous study and our
knowledge.9 In addition, most of the NFGNB from patients
with nosocomial NFGNB bacteremia in Taiwan were resis-
tant to gentamicin. Given that other studies revealed
increasing resistance to gentamicin in P. aeruginosa iso-
lates, gentamicin should not be administered alone
empirically for NFGNB infection in Taiwan before the drug
susceptibility is available. Among the four aminoglycosides
we tested in our study, amikacin had the broadest spectrum
coverage against NFGNB, including P. aeruginosa (suscep-
tibility: 98%), A. nosocomialis (susceptibility: 96%), and A.
pittii (susceptibility: 91%).
There are limitations to the current study. Firstly, we
identified patients with healthcare-associated bloodstream
infections and randomly selected from the available pre-
served blood isolates for aminoglycoside susceptibility
testing due to the limitation of faculties. The true disease
burden of each NFGNB therefore could not be assessed.
Secondly, we only did the susceptibility testing to amino-
glycosides without investigating the susceptibility profiles
of other antibiotics and the possible resistant mechanisms
to aminoglycosides. Therefore, the relationships of cross-
resistance or coresistance of aminoglycosides with other
antimicrobial agents were unknown. Finally, no clinical or
treatment data of patients were extracted in our study. The
in vitro susceptibility to aminoglycosides may not be fully
translated into the clinical treatment response in vivo.
In summary, genospecies of A. baumannii complex
possessed heterogeneous susceptibility to aminoglycosides.
Amikacin had the greatest in vitro activity against P. aer-
uginosa, A. nosocomialis, and A. pittii, whereas tobramycin
and isepamicin were less potent against A. pittii. Further
in vivo clinical data and continuous resistance monitoring
will be warranted to establish clinical recommendations for
aminoglycosides treatment against NFGNB in patients with
healthcare-associated bloodstream infections in Taiwan.
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